Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole Risk Assessment in Metastatic Breast Cancer
NCT00241046Phase 4Terminated
- Sponsor
- Novartis
- Start
- Apr 2002
- Primary completion
- Mar 2005
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, open-label, single-arm trial of letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Comparison of the individual pretherapeutic predictions from the computer or doctor with the patient data. Started Apr 2002; status: terminated.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00241046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241046.